Comparison · NCT04633889-sae
Deferoxamine vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deferoxamine vs Placebo: serious adverse events. Trial comparisons, record NCT04633889-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04633889-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.152 | 0.104 | 0.218 | wilson | |
| Risk in group 2 | 0.167 | 0.116 | 0.234 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0143 | -0.0978 | 0.0691 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.914 | 0.544 | 1.54 | log | |
| Odds ratio, group 1 over group 2 | 0.898 | 0.484 | 1.67 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Deferoxamine than on Placebo | 69.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deferoxamine | Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours | 23 | 151 | EG000 |
| Group 2 | Placebo | Normal saline (240mL) intravenous infusion over 12 hours | 25 | 150 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality was measured from initiation of the study drug until discharge from the index hospital admission during which the study drug was administered, up to 1 year; Vasoactive-Inotropic Score (VIS) was measured for 24-hours following study drug initiation; anaphylaxis was measured throughout the 12 hour study drug administration period; Infection/Sepsis and ARDS were measured for 7 days following the study drug administration.
Source ClinicalTrials.gov
Trial
- Title
- Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
- NCT number
- NCT04633889
- Phases
- PHASE2
- Conditions
- Acute Kidney Injury
- Interventions
- Deferoxamine, Normal saline
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2026-01-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04633889?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04633889-sae